Company profile

Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated in
Location
Fiscal year end
SEC CIK

PFE stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Calendar

7 May 20
4 Jun 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Sep 19 Jun 19 Mar 19
Revenue 12.03B 12.68B 13.26B 13.12B
Net income 3.41B 7.68B 5.06B 3.89B
Diluted EPS 0.61 1.36 0.89 0.68
Net profit margin 28.35% 60.60% 38.12% 29.65%
Operating income* 4.27B 11.13B 4.52B 4.68B
Net change in cash -634M 1B -153M 798M
Cash on hand 2.15B 2.79B 1.78B 1.94B
Cost of revenue 2.38B 2.6B 2.58B 2.43B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 53.65B 52.55B 52.82B 48.85B
Net income 11.19B 21.36B 7.25B 6.99B
Diluted EPS 1.87 3.52 1.17 1.11
Net profit margin 20.85% 40.64% 13.72% 14.30%
Operating income* 13.17B 13.53B 9.51B 10.14B
Net change in cash -203M -1.25B -1.05B 298M
Cash on hand 1.14B 1.34B 2.6B 3.64B
Cost of revenue 11.25B 11.23B 12.32B 9.65B

Financial data from Pfizer earnings reports. *Asterisk values are approximate.

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
29 May 20 Albert Bourla Phantom Stock Units SSP Common Stock Grant Aquire A 38.19 13 496.47 77,549
29 May 20 John D Young Phantom Stock Units SSP Common Stock Grant Aquire A 38.19 11 420.09 46,632
29 May 20 Dawn Rogers Phantom Stock Units SSP Common Stock Grant Aquire A 38.19 52 1.99K 15,996
29 May 20 Rady A Johnson Phantom Stock Units SSP Common Stock Grant Aquire A 38.19 4 152.76 5,521
29 May 20 Jennifer B. Damico Phantom Stock Units SSP Common Stock Grant Aquire A 38.19 31 1.18K 9,954
70.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2351 2463 -4.5%
Opened positions 115 292 -60.6%
Closed positions 227 108 +110.2%
Increased positions 960 987 -2.7%
Reduced positions 1080 942 +14.6%
13F shares
Current Prev Q Change
Total value 1.38T 1.49T -7.4%
Total shares 3.9B 3.99B -2.1%
Total puts 34.5M 28.95M +19.2%
Total calls 24.3M 25.65M -5.3%
Total put/call ratio 1.4 1.1 +25.8%
Largest owners
Shares Value Change
Vanguard 461.98M $15.08B +2.7%
BLK BlackRock 424.07M $13.84B -0.5%
STT State Street 292.62M $9.55B +0.3%
Capital World Investors 224.81M $7.34B +19.1%
Wellington Management 218.68M $7.14B +12.9%
Geode Capital Management 89.95M $2.93B +1.0%
BAC Bank of America 86.67M $2.83B -12.4%
NTRS Northern Trust 70.02M $2.29B -1.6%
State Farm Mutual Automobile Insurance 56.54M $1.85B 0.0%
BK Bank Of New York Mellon 56.09M $1.83B -6.2%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -59.37M EXIT
Fisher Asset Management 5.45M -39.93M -88.0%
Capital World Investors 224.81M +36.09M +19.1%
Wellington Management 218.68M +24.95M +12.9%
Capital International Investors 8.22M -13.78M -62.6%
Massachusetts Financial Services 39.2M -12.62M -24.4%
BAC Bank of America 86.67M -12.24M -12.4%
Vanguard 461.98M +12.02M +2.7%
GS The Goldman Sachs Group, Inc. 33.13M -11.45M -25.7%
Renaissance Technologies 2.6M -10.5M -80.1%

Financial report summary

?
Risks
  • DEPENDENCE ON KEY IN-LINE PRODUCTS
  • RESEARCH AND DEVELOPMENT INVESTMENT
  • SPECIALTY PHARMACEUTICALS
  • PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
  • BIOPHARMACEUTICAL WHOLESALERS
  • BUSINESS DEVELOPMENT ACTIVITIES
  • PRICING AND REIMBURSEMENT
  • DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
  • INTERACTIONS WITH HEALTHCARE PROFESSIONALS AND GOVERNMENT OFFICIALS
  • CHANGES IN LAWS AND ACCOUNTING STANDARDS
  • ENVIRONMENTAL CLAIMS AND PROCEEDINGS
  • THIRD PARTY INTELLECTUAL PROPERTY CLAIMS
  • INFORMATION TECHNOLOGY AND SECURITY
  • PENDING COMBINATION OF UPJOHN WITH MYLAN
  • CONSUMER HEALTHCARE JOINT VENTURE WITH GSK
  • THE GLOBAL ECONOMIC ENVIRONMENT
  • FOREIGN EXCHANGE AND INTEREST RATE RISK
  • MARKET FLUCTUATIONS IN OUR EQUITY INVESTMENTS
  • COST AND EXPENSE CONTROL/UNUSUAL EVENTS/FAILURE TO REALIZE THE ANTICIPATED BENEFITS OF STRATEGIC INITIATIVES AND ACQUISITIONS
  • INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: Abrilada, absorbing, academic, accurately, adding, Aid, air, AML, amplify, Amsparity, ankylosing, antiviral, apparently, Appellate, arisen, axial, barring, battle, BCG, benchmark, BioNTech, bladder, BRAF, Branch, Brazilian, capsule, cetuximab, Chantix, chemoradiotherapy, cleaning, combat, commensurate, compel, comply, concentrate, confirmatory, confronting, contact, CRC, Cresemba, CRL, CRT, custodian, cytarabine, Daurismo, delinquency, denial, distancing, doctor, duration, EBITDA, eliminating, enjoined, enrolled, enrollment, Erbitux, fiduciary, fighting, Florida, forma, Fosun, franchise, frequently, glasdegib, home, IBT, idiopathic, ImClone, immaterial, inappropriate, Indenture, ineffective, interbank, interventional, intraperiod, intubation, investee, Irrungattukottai, issuer, job, join, joined, juvenile, low, Lyme, MabThera, macroeconomic, margin, mCSPC, Mellon, Mexican, mild, mRNA, NDMA, novo, NYU, Ono, operationally, outbreak, oversee, pandemic, parallel, payout, peak, penetration, perpetual, peso, physical, plaque, pool, potent, precipitate, preliminarily, preplanned, prevalent, proceed, prolonged, proprietary, protease, psoriatic, PTAB, rapid, raw, rebound, recoup, recouped, recruitment, redecide, refilling, refocused, reliant, repay, respond, responded, responding, restart, restored, resume, ritlecitinib, Roche, shortly, slowdown, society, somatrogon, specialty, stabilized, statistically, stemming, stone, strict, succeeded, Sugen, suggest, suitability, Summarized, superior, suppurativa, surface, surgical, survival, tolerated, Track, tracked, tracking, trajectory, transmission, transport, travel, troubled, underserved, unemployment, unforeseen, unprecedented, unsuccessful, untreated, unturned, upward, vacated, VAI, Valneva, varenicline, viable, visit, Viwit, Vyndamax, wake, widespread, yuan, Zantac, Zavicefta, Zinforo
Removed: accountability, accountable, achieving, achondroplasia, activating, actuarial, adjust, advocate, aforementioned, aggressive, aging, Alembic, amounted, anticipation, AOCI, applied, arm, arrive, Article, assistance, assured, attributed, AWP, Azar, BeneFIX, bidding, bioequivalence, bioequivalent, bipartisan, borrowing, bosutinib, breakthrough, Brexit, Bringing, British, call, callable, Cangialosi, capability, cease, centralization, centralized, cervix, channel, Citibank, clostridium, cohesive, collaboratively, colon, commence, Communication, considerable, Consolidation, constant, Conversely, Cooperation, costly, Council, counterclaim, criteria, decided, declaration, declaratory, declining, dedicated, deductible, delivered, demanding, demonstrated, demonstrating, dependent, diagnose, Dilution, disaggregate, discontinuation, discount, discounted, discover, dismissal, disputed, dissolving, diversity, dosing, dramatic, dramatically, dwarfism, dynamic, earlier, earliest, effectively, efficiently, EGFR, EH, electorate, emphasized, employ, encounter, encouraging, enhancing, entitlement, epidermal, ertugliflozin, Essential, establishing, exacerbated, exceed, execution, exercise, exercised, expedient, expensive, explanation, export, failing, feature, Finalizing, FL, fleet, flexibility, flexible, forestalling, formally, Fragmin, framework, fraud, gap, Gavi, generating, genetic, Genotropin, Goldman, grant, hard, headcount, hemophilia, Herceptin, hindsight, Hisun, House, identification, IH, immunization, implicit, improving, Imputed, influence, inhalation, input, intensive, internally, invalidate, issuing, judicial, junction, landscape, lease, legislative, LEP, leveraging, licensed, Lisbon, Loretta, managerial, matrix, MCC, measuring, Medrol, meeting, met, Michigan, midterm, migrate, minimum, model, modernize, modestly, modify, moving, MSN, multilateral, municipal, mutual, negatively, negotiated, NOAC, nonemployee, notification, NYSE, OAI, OECD, officially, optimal, optimization, orally, originator, outlining, package, PAP, Parliament, participate, passed, patchwork, path, Peripheral, PF, Pharmacology, Portage, pose, positioning, powder, practical, preclude, premarket, premium, President, Prism, Pristiq, privately, promising, promote, promoted, propionate, proportional, provincial, prudent, PsA, pursuit, QCE, quickly, rationalizing, realigning, reallocated, rebate, receptor, reclassification, rectum, redeploy, refacto, referencing, referendum, refuse, register, reinvested, relocate, remediate, renal, renamed, rent, rental, repatriated, replace, represented, requiring, Residual, retirement, retrospectively, reward, Rheumatology, rivipansel, robust, ROU, round, routine, Roxane, salmeterol, screen, scrutiny, secure, seize, Senate, separately, serving, SFJ, shift, Shire, shortage, sickle, signal, simplification, simplified, skip, source, space, statute, stop, streamline, stronger, sublease, suboptimal, subsequently, substituted, sufficiently, supplier, surrogate, sustainability, sustained, switch, tablet, targeting, technically, technological, tendering, thereunder, transparency, trastuzumab, Treaty, trend, true, Tygacil, ulcerative, Unallocated, unclear, unconstitutional, undiscounted, unified, Unregistered, upgrade, Urbanization, usage, variant, vast, Vfend, Vice, virtually, weaken, wild, Xyntha, Zyvox